Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. - Shernan,SK.; Fitch,JC.; Nussmeier,NA.; Chen,JC.; Rollins,SA.; Mojcik,CF.; Malloy,KJ.; Todaro,TG.; Filloon,T.; Boyce,SW.; Gangahar,DM.; Goldberg,M.; et al. (Ann Thorac Surg, 2004)